'Role of Tranexamic acid on blood loss in hip fracture patients'

Phase 2

Recruiting

• Conditions: Intra capsular neck of femur fractures; Surgery - Other surgery; Injuries and Accidents - Fractures

• Registration Number: ACTRN12617000391370
• Lead Sponsor: epean Hospital (Nepean Blue Mountain Local Health District)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-03-16
• Last Update Posted: 3 February 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Patients with intra-capsular neck of femur fractures undergoing hemiarthroplasty (cemented or uncemented) or total hip arthroplasty (cemented, hybrid or uncemented) within 48 hrs from the time of injury.

Exclusion Criteria

1.Neck of femur fractures requiring fixation by other methods e.g. by cannulated screws, dynamic hip screw or intra-medullary nail device.
2.Patients presenting 48 hours from the time of injury. This includes patients transferred to Nepean hospital from other hospitals.
3.Contra-indication to the administration of TA -
Previous history of thrombosis
Active thromboembolic disease (DVT,PE and cerebral thrombosis)
Other contraindication to the use of TA :
Patients with acquired disturbances of colour vision
Patients with subarachnoid haemorrhage
Previous history of seizure
Creatinine clearance < 30ml/min
Hypersensitivity to TA
4.Patients who are unable to provide informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified